Email Updates

You are here

Home

9 APRIL 2021 VOLUME 23 ISSUE 14

Media Coverage

  • Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists

    HIV research and development has a diversity problem. While this is not a new problem, it’s one that continues to draw attention—particularly during this pandemic year, when we’ve seen considerably low recruitment of people living with HIV in COVID-19 vaccine clinical trials and, subsequently, a renewed interest toward diminishing those gaps in forthcoming HIV research.

    April 9, 2021
    General
    The BodyPro

  • One Important Lesson from the HIV Epidemic: Optimism Is a Powerful Public Health Weapon

    After a year that, for must of us, has been a blur of panic-inducing headlines, good news about the coronavirus sounds like an oxymoron. Monica Gandhi, an infectious disease specialist and the associate division chief of the Division of HIV, Infectious Diseases, and Global Medicine at UCSF/San Francisco General Hospital, wants to change that. After decades of working on the HIV epidemic, Gandhi has learned that fear-based messaging isn’t always effective, and she hopes to help the public health community learn from past mistakes rather than repeating them.

    April 8, 2021
    General
    Mother Jones

  • HIV Data Bites: Recent Advances in Broadly Neutralizing Antibodies for HIV Prevention

    Although very few biomedical HIV prevention options are available at the moment—the only form officially approved by the US Food and Drug Administration is daily oral pre-exposure prophylaxis (PrEP)—plenty of additional methods are being explored, from periodic injections to implants to mRNA vaccines akin to those used against COVID-19. One very active subfield within this area is the development of interventions involving broadly neutralizing antibodies, or bNAbs.

    April 8, 2021
    Antibody Related Research
    The BodyPro

  • Can Unprecedented Success in COVID Vaccine Development Boost Prospects for an HIV Vaccine?

    In February 2020, just as the COVID pandemic began its rapid global spread, a major HIV vaccine trial called HVTN 702, or Uhambo, was halted for lack of efficacy. Researchers and advocates had high hopes for Uhambo, building as it did on the RV144 trial, which provided the first evidence that an HIV vaccine could create a partially protective immune response. But Uhambo, like several studies before it, ended in disappointment.

    April 7, 2021
    HIV Vaccine
    Science Speaks

  • Battle Coronavirus but Don’t Forget About HIV

    Today, we mark World Health Day. The theme for this year is building a fairer, healthier world for everyone. This year is especially challenging as we mark the day amid a pandemic, and at a time when the third wave of COVID-19 has hit Kenya occasioning a partial lockdown. Sadly, the COVID-19 pandemic has disrupted healthcare and abruptly undercut health gains made over many years, putting the lives of millions of Kenyans at great risk.

    April 7, 2021
    General
    The Standard

  • More Than Prevention: PrEP Enhances Income, Trust, and Intimacy in Uganda

    PrEP is about more than HIV prevention, according to women working in the sex and entertainment industry in Kampala, Uganda. Their motives for taking PrEP were multi-faceted and included condomless sex to both generate more income and to maintain trust and intimacy in primary relationships.

    April 6, 2021
    Male and Female Condoms, PrEP
    aidsmap

  • Leader Needed To Fight Another Global Pandemic — HIV

    During a year when the virus that causes COVID-19 demonstrated how swiftly it could change the world, the opening at the helm of the US President’s Emergency Plan for AIDS Relief showed a much larger — and potentially more powerful — force at a standstill, even as the critical goal of ending another global public health threat hung in the balance.

    April 6, 2021
    General
    The Hill

  • Research Shows Promising Development in Hunt for HIV Vaccine

    After more than 30 years of attempts, there may be a promising advance in the search for a vaccine for HIV, the virus that causes AIDS if left untreated.

    April 6, 2021
    HIV Vaccine
    ABC News

  • Risky Sexual Behaviours Increasing Among Young People in Nigeria

    Inconsistent condom use and other risky practices particularly common among women and those with limited HIV knowledge, highlighting the need for comprehensive sexual health education.

    April 6, 2021
    Male and Female Condoms
    Avert

  • Zim Achieves HIV Prevention Target

    Zimbabwe has achieved the 90-90-90 target on HIV prevention and is now working on the 95-95-95 target for 2025, while the mortality significantly declined by almost 72 percent in the 10 years between 2010 and 2020, the National AIDS Council (NAC) has revealed.

    April 5, 2021
    The Herald Zimbabwe

  • Full Contraception Access Is Critical to Defeating HIV

    Behind the COVID-19 headlines of 2020, the HIV pandemic continued to claim hundreds of thousands of lives and newly infected over 1.5 million people. For those in the HIV movement, 2020 also marked the endpoint of several global targets for preventing HIV, including the UNAIDS goal of reducing new infant infections to fewer than 20,000 per year. Unfortunately, we missed that goal – and we missed by a lot. The global health community must now redesign its HIV programs to meet this target, and new modeling suggests that expanding women’s access to contraception might be the key.

    April 5, 2021
    Hormonal Contraceptives and HIV
    HIV Plus Mag

  • Long-Acting ART Is Here. How Do We Make It Work for Our Patients?

    In January, the US Food and Drug Administration (FDA) approved cabotegravir/rilpivirine (CAB/RPV, Cabenuva) monthly injections for antiretroviral treatment (ART), marking a major leap forward in treatment options and thereby reducing dosing days from 365 to 12—and, likely soon, six—days per year. Next up: injections for pre-exposure prophylaxis (PrEP).

    April 5, 2021
    Treatment
    The BodyPro

  • As CROI 2021 Attests, the PrEP Revolution Is Coming

    David Alain Wohl, M.D., discusses highlights and clinical takeaway messages from the 2021 Conference on Retroviruses and Opportunistic Infections (CROI 2021), which took place in March. In the video, Wohl talks through new findings on HIV prevention, especially those that aim to expand and transform the options available to people for pre-exposure prophylaxis (PrEP).

    April 5, 2021
    PrEP
    The BodyPro

  • The ‘Elite Controllers’ Who Can Naturally Suppress HIV

    Research into how some HIV-positive people keep the virus at bay promises to yield new treatment possibilities, from vaccines to gene therapies.

    April 4, 2021
    Cure, General
    The Guardian

Published Research

Announcements